14,355 Stryker Corporation $SYK Shares Purchased by Verdence Capital Advisors LLC

Key Points

• Verdence Capital Advisors more than doubled its Stryker stake in the third quarter, purchasing 14,355 additional shares for a total holding of 28,206 shares valued at approximately $7.8 million.
• Institutional investors own 77.09% of Stryker, while analysts maintain a generally positive outlook with a consensus “Moderate Buy” rating and a $369 target price.
• Stryker reported quarterly EPS of $3.69, exceeding estimates, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, representing a 1.1% yield.

Verdence Capital Advisors LLC grew its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 103.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,206 shares of the medical technology company's stock after purchasing an additional 14,355 shares during the period. Verdence Capital Advisors LLC's holdings in Stryker were worth $7,768,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Bank of America Corp DE bought a new stake in Stryker in the 2nd quarter valued at about $1,404,284,000. Legal & General Group Plc acquired a new position in Stryker during the 2nd quarter worth approximately $707,212,000. Jupiter Topco LLC bought a new position in Stryker in the second quarter worth approximately $681,581,000. Corient Private Wealth LP bought a new position in Stryker in the second quarter worth approximately $323,035,000. Finally, Flossbach Von Storch SE acquired a new stake in Stryker in the second quarter valued at approximately $464,506,000. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SYK. Raymond James Financial set a $370.00 target price on Stryker in a research report on Friday, July 31st. JPMorgan Chase & Co. dropped their price objective on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Sanford C. Bernstein reiterated a "market perform" rating on shares of Stryker in a report on Wednesday, October 7th. Royal Bank Of Canada decreased their target price on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Finally, UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $369.00.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Trading Down 0.2%

NYSE SYK opened at $306.50 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $295.95 and a 200 day simple moving average of $326.09. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a market capitalization of $117.56 billion, a P/E ratio of 31.76, a PEG ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the firm earned $3.13 EPS. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's payout ratio is 36.48%.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.